Uncomplicated Urinary Tract Infections Market Infographic
Uncomplicated Urinary Tract Infections Market

Urinary Tract Infection (UTI) is the most common bacterial infection caused by gram-negative bacteria, where gram-positive pathogens may also be involved. It is an infection in any part of the urinary system, which includes kidneys, ureters, bladder, and urethra. UTIs are amongst the most frequent bacterial infections. The clinical phenotypes of UTI are heterogeneous and range from benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis, and severe urosepsis. 


Uncomplicated Urinary Tract Infections Epidemiology Segmentation in the 7MM from 2018- 2030

  • Total Uncomplicated Urinary Tract Infections Occurrence-specific Cases
  • Total Uncomplicated Urinary Tract Infections Diagnosed Cases
  • Total Uncomplicated Urinary Tract Infections Age-specific Cases
  • Total Uncomplicated Urinary Tract Infections Pathogen-specific Cases
  • Total Uncomplicated Urinary Tract Infections Treated cases (across lines)


Uncomplicated Urinary Tract Infections Epidemiology Insights Observed in 2020


  • The Uncomplicated Urinary Tract Infections diagnosed cases in the 7MM were observed to be 19.3 million.
  • The total Uncomplicated Urinary Tract Infections first-line pool treated cases in the 7MM were found to be 18.4 million and Recurrent pool treated cases were estimated to be 6.6 million.
  • The total Uncomplicated Urinary Tract Infections occurrence-specific cases in the United States was observed to be 14.7 million, in the EU-5 was found to be 13.8 million, and in Japan, it was estimated to be 6.7 million.


Uncomplicated Urinary Tract Infections Market Insights


The Uncomplicated Urinary Tract Infections Market is expected to grow at a significant CAGR of 11.9% during the study period (2018-2030)


Uncomplicated Urinary Tract Infections Market Drivers


  • Therapies with a novel mechanism of action are under investigation
  • Use of combination therapies for a solution to antibiotic resistance


Uncomplicated Urinary Tract Infections Market Barriers


  • The burden of recurrent UTIs
  • Inappropriate empirical treatment


Uncomplicated Urinary Tract Infections Emerging Therapies


The emerging drugs in the Uncomplicated Urinary Tract Infections market are-


  • GSK2140944 (Gepotidacin)
  • Sulopenem Etzadroxil/Probenecid
  • Uromune (MV140)
  • ExPEC Vaccine (ExPEC10V and ExPEC4V)
  • GSK3882347, and others


Uncomplicated Urinary Tract Infections Key Players


The key companies in the Uncomplicated Urinary Tract Infection market are-


  • GlaxoSmithKline/Fimbrion Therapeutics
  • Janssen Pharmaceuticals
  • Inmunotek
  • Iterum Therapeutics
  • GlaxoSmithKline, and many others